|
KMID : 1140220200250040213
|
|
대한암예방학회지
2020 Volume.25 No. 4 p.213 ~ p.222
|
|
|
Recent Advances in the Development of TGF-β Signaling Inhibitors for Anticancer Therapy
|
|
Lee Ho-Jae
|
|
|
Abstract
|
|
|
|
TGF-β is a multifunctional cytokine that plays an important role in both physiologic and pathologic processes, including cancer. Importantly, TGF-β has a dual role in tumorigenesis, acting as a tumor suppressor or a tumor promoter, depending on the stage of tumor development. The aberrantly upregulated production of TGF-β has been strongly implicated in tumor progression, angiogenesis, and metastasis, as well as immune evasion. Therefore, hyperactivated TGF-β signaling is considered a potential therapeutic target for cancer therapy. Numerous inhibitors of overactivated TGF-β signaling have been developed, and some of them are currently in clinical trials. This review focuses on the TGF-β signaling that contributes to tumor progression and immune evasion in the tumor microenvironment and presents recent achievements on TGF-β signaling inhibition as a single or combined therapeutic approach in cancer therapy.
|
|
|
KEYWORD
|
|
|
TGF-β, Tumor microenvironment, Tumor escape, Antineoplastic agents, Immune checkpoint inhibitors
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|
|